Initial Staging of Differentiated Thyroid Carcinoma: Continued Utility of Posttherapy131I Whole-Body Scintigraphy
- 1 March 2008
- journal article
- research article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 246 (3), 887-894
- https://doi.org/10.1148/radiol.2463061328
Abstract
To retrospectively compare pretherapy iodine 123 ((123)I) and posttherapy iodine 131 ((131)I) sodium iodide whole-body scintigraphy of patients with newly diagnosed differentiated thyroid cancer to determine if there is significant and clinically relevant discordance of nonphysiologic iodide-avid foci (IAFs) between the two examinations. This study was approved by the Institutional Review Board, the requirement for informed consent was waived, and the study complied with HIPAA. The authors identified 108 patients (88 women, 20 men; age range, 16-86 years; mean, 47.5 years; 45 patients younger than 45 years, 63 patients 45 years and older) who previously had undergone total or near-total thyroidectomy for differentiated thyroid carcinoma. Each patient had undergone a pretherapy ( 123)I whole-body scan followed by a posttherapy ( 131)I whole-body scan. The number and location of IAFs were recorded on both scans. Data were compared by using a Wilcoxon signed rank test for paired data and assessed clinical relevance based on changes in tumor staging. Posttherapy ( 131)I whole-body scans revealed additional IAFs outside the thyroid bed not detected on pretherapy ( 123)I scans in 21 (19%, P < .001) of 108 patients. Nineteen (90%) of these 21 had IAFs in new locations (P < .001), with tumor upstaging of 11 (59%, 10% of total) of those 19 patients; six (55%, 6% of total) of those 11 had scintigraphic patterns consistent with unsuspected metastatic disease. Concordant scintigraphic patterns were observed in 87 (81%) of 108. In patients with newly diagnosed differentiated thyroid cancer who had undergone thyroidectomy and ( 131)I ablation, posttherapy ( 131)I whole-body scintigraphy revealed new IAFs in 18% and clinical upstaging occurred in 10% of patients compared with pretherapy ( 123)I whole-body scintigraphy. Therefore, posttherapy ( 131)I whole-body scintigraphy provides incremental clinically relevant information as it helps to establish the true extent of IAFs and may contribute to altering of staging.Keywords
This publication has 16 references indexed in Scilit:
- I-123 Whole Body Scanning: Case Report and DiscussionClinical Nuclear Medicine, 2005
- Stunning with131I Diagnostic Whole-Body Imaging of Patients with Thyroid CancerRadiology, 2005
- Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123IEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- I-123 Diagnostic Thyroid Tumor Whole-Body Scanning with Imaging at 6, 24, and 48 HoursClinical Nuclear Medicine, 2002
- The role of 123I‐diagnostic imaging in the follow‐up of patients with differentiated thyroid carcinoma as compared to 131I‐scanning: avoidance of negative therapeutic uptake due to stunningClinical Endocrinology, 2001
- The Nonimpact of Thyroid Stunning: Remnant Ablation Rates in 131I-Scanned and Nonscanned IndividualsJournal of Clinical Endocrinology & Metabolism, 2001
- Superiority of Iodine-123 Compared with Iodine-131 Scanning for Thyroid Remnants in Patients with Differentiated Thyroid CancerClinical Nuclear Medicine, 2001
- Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma.European Journal of Nuclear Medicine and Molecular Imaging, 1998
- 74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancerNuclear Medicine Communications, 1997
- Influence of Diagnostic Radioiodines on the Uptake of Ablative Dose of Iodine-131Thyroid®, 1994